





الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونُسُ بَرَسِيْتِي اِسْلَامُهُ اِنْتَارَا بَعَثْنَا مَلِيْسِيَا

Garden of Knowledge and Virtue

IJOHS

*International Journal
of Orofacial and
Health Sciences*

A scientific journal
published by Kulliyah of
Dentistry, IIUM, Malaysia



ISSN 2716-5434



9 772716 543003

VOL. 1 ISSUE 1

2020



International Journal of Orofacial and Health Sciences

Editorial Board

Chief Editor	: Professor Dr. Zainul Ahmad Rajion
Editor	: Dr. Salwana Supa'at
	: Dr. Basma Ezzat Mustafa Alahmad
	: Assoc. Prof. Dr. Khairani Idah Mokhtar@Makhtar
	: Assoc. Prof. Dr. Solachuddin J.A. Ichwan
	: Assoc. Prof. Dr. Muhannad Ali Kashmoola
	: Dr. Widya Lestari
	: Dr. Azlini Ismail
	: Dr. Mohd Hafiz Arzmi
	: Dr. Mohamad Shafiq Mohd Ibrahim

Aims and Scope:

International Journal of Orofacial and Health Sciences (IJOHS) is a peer reviewed biannual international journal dedicated to publish high quality of scientific research in the field of orofacial sciences, health sciences and interdisciplinary fields, including basic, applied and clinical research. The journal welcomes review articles, original research, case reports and letters to the editor. Areas that are covered include but are not limited to dental sciences, oral microbiology and immunology, oral maxillofacial and craniofacial surgery and imaging, dental stem cells and regenerative medicine, dental biomaterial, oral maxillofacial genetic and craniofacial deformities.

Published by:

Kulliyah of Dentistry,
International Islamic University Malaysia (IIUM),
Indera Mahkota,
25200 Kuantan, Pahang, Malaysia.

Printed and distributed by:

Kulliyah of Dentistry,
International Islamic University Malaysia (IIUM),
Indera Mahkota,
25200 Kuantan, Pahang, Malaysia.

All rights reserved; No part of this publication maybe reproduced, stored in a retrieval system, or transmitted in any form, or by any means, electronic or otherwise, without prior permission of the publisher.

CONTENTS

EDITORIAL

Introduction to IJOHS 3

REVIEW ARTICLES

Genetics of malocclusion: A review 4

ORIGINAL ARTICLES

Potential antibacterial effects of flaxseed and *Nigella sativa* extracts on *Streptococcus pyogenes* 11

Dental treatment needs among patients undergoing screening at a university-based dental institution in Kuantan, Pahang, Malaysia 18

Analysis of the anti-cancer effect of ethyl-p-methoxycinnamate extracted cekur (*Kaempferia galanga*) on cancer cell lines with wild-type and null p53 28

Radiographic findings in panoramic radiographs of patients attending Kulliyah of Dentistry, IIUM 34

Isolation of *Candida* species in children and their biofilm-forming ability on nano-composite surfaces 40

Analysis of the anti-cancer effect of ethyl-p-methoxycinnamate extracted cekur (*Kaempferia galanga*) on cancer cell lines with wild-type and null p53

Solachuddin Jauhari Arief Ichwan^{1§}, Syahirah Sazeli^{2§}, Widya Lestari^{1*}

¹Department of Fundamental Dental and Medical Sciences, Kulliyah of Dentistry, International Islamic University Malaysia, 25200, Pahang, Malaysia

²Faculty of Medicine, Universiti Kuala Lumpur (Royal College of Medicine Perak), Malaysia

Abstract

This study aimed to examine the in-vitro anti-cancer potential of ethyl-p-methoxycinnamate (EPMC), the major constituent of *Kaempferia galanga* (*K. galanga*) in selected human lung adenocarcinoma cells line A549 (p53 wild-type) and H1299 (p53 null). The involvement of p53 pathway in the anti-cancer effect of EPMC on selected cells was determined using MTT assay and Real-time PCR. The MTT results show that EPMC induces cytotoxicity in a dose-dependent manner in A549 cancer cell lines containing the p53 wild-type gene. Meanwhile, our RT-PCR results indicate that the apoptotic activity of EPMC does not involve the p53 pathway. Overall, these results indicate that EPMC compounds of *K. galanga* stimulates in vitro cytotoxic and apoptotic activity unrelated to the p53 pathway.

Keywords: Ethyl-P-Methoxycinnamate, *Kaempferia Galanga*, p53

[§]Both authors contributed equally to this work.

*Corresponding Author

Email address: drwidya@iium.edu.my

Tel: +6019-946 9755

Introduction

Cancer is a major public health problem worldwide. There are many factors that may contribute to the development of cancer. In many cases, cancer involves mutations in protein-encoding genes that regulate cell division. Eventually, more genes become mutated because the genes that normally repair DNA damage become themselves mutated and cease to function. The amplification of mutations in the cell causes further abnormalities in the cell and its daughter cells.

TP53 (tumor suppressor gene p53) plays a significant role in protecting cells from malignancies. It is well-known that

p53 suppresses tumor formation and protects against DNA damage by inducing cell cycle arrest, DNA repair or apoptosis (Wang and Sun, 2010). p53 induces cell cycle arrest by trans-activating genes such as p21 (CDK-inhibitor 1, cyclin dependent kinase) (Chiang *et al.*, 2013). Furthermore, p53 initiates apoptosis via trans-activating pro-apoptotic proteins such as PUMA (p53 upregulated modulator of apoptosis) (Bai and Wang, 2014), BAX (Bcl-2-associated X protein) or FAS (cell surface death receptor) (Wang and Sun, 2010).

However, the p53 is often mutated in cancer (Klein and Vassilev, 2004).

Evidence suggests that, mutations or deletions in the TP53 gene are present in nearly 50% of human cancers and primarily results in impaired tumor suppression function (Wang *et al.*, 2012). Loss of p53 functionality leads to the proliferation of damaged cells that may subsequently transfer the mutations to the next generation. It is believed that it is through this mechanism that deregulation of p53 often leads to the formation of tumors (Khoury and Domling, 2012).

Due to the high occurrence of p53 mutations in human tumors, this tumor suppressor is a key target for novel anticancer therapies. Several research teams have dealt with the possibility of restoring p53 function to treat cancer. Many novel molecules have been identified so far to restore p53 wild-type conformation and thereby recover its tumor suppressive function (Hientz *et al.*, 2017).

Thus far, a number of studies has reported that EPMC, a major constituent of volatile oil of *K. galanga* possesses in vitro anti-cancer activities on various cancer cell lines such as human colon cancer SW620, cervical cancer C33A, breast cancer MCF-7 cell lines and oral cancer HSC-3 and Ca922 cell lines (Amuamuta *et al.*, 2017; Omar *et al.*, 2017; Omar *et al.*, 2016; Ichwan *et al.*, 2019).

Despite these promising results, the question of the role of *K. galanga* in the p53 pathway remains unknown. Therefore, the objective of this study was to determine the in vitro anti-cancer potential of EPMC extracted from *K.galanga* against human cancer cell lines A549 (lung cancer, p53 wild-type) and H1299 (lung cancer, p53 null). The study also aims to explore the involvement of p53 pathway in anticancer mechanism of EPMC extract on human cancer cell lines.

Materials and Methods

Cell subculturing and maintenance

The human lung adenocarcinoma cells A549 (wild-type p53) and H1299 (null p53) were kindly provided by Prof. Dr. Masa Aki Ikeda, Tokyo Medical and Dental University, Japan. The cells were grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin mixture in a humidified incubator, 5% CO₂ at 37°C.

MTT assay

Cell viability was measured by the ability of the cells to convert soluble MTT into an insoluble formazan crystal. The assay was performed according to the protocol previously described (Ichwan *et al.*, 2014) with slight modifications. Exponentially growing cells were subcultured in 96-well plates at an initial density of 2x10⁴/ well. The cells were exposed to pre-defined concentrations of EPMC and doxorubicin for 24 hours.

After 24 hours of incubation, the medium was removed and the cells were washed with PBS. Cell viability was determined by adding 20 µL MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide at a concentration of 5mg/ml (in PBS). Cells were incubated at 37°C in humidified atmosphere for 4 hours. The formazan crystals were dissolved in 100 µL of dimethylsulfoxide (DMSO) for 1 hour. The absorbance was measured in a spectrophotometer at a wavelength of 570nm (reference: 630 nm).

Total RNA extraction

The total RNA Mini Kit was acquired from Geneaid (Taiwan). RNA extraction was performed following the manufacturer's protocol.

Complementary DNA (cDNA) preparation

cDNA synthesis was conducted using ReverTra Ace® qPCR RT Master Mix Kit (Toyobo, Japan) based on manufacturer's instructions. A total of 8 µl of solution consisting of 4X DN Master Mix, RNA template, and nuclease-free water was prepared. After incubation for 5 min, 5x Master Mix was added to the solution to a total of 10 µl of reverse transcription solution. Then, the solution was incubated at 37 °C for 15min and heated at 98 °C for 5 min to obtain cDNA.

Quantitative PCR (qPCR)

The mRNA expressions of p21 and PUMA were determined by qRT-PCR. The RT-qPCR was performed using the Quantitect SYBR® Green PCR (Qiagen) kit according to manufacturers's instructions. The qRT-PCR reaction mixture consists of 2x QuantiTect SYBR Green PCR master mix, pre-developed gene expression assays, primers mix and H₂O to a final volume of 14 µL were prepared. The relative expression level of the mRNA sample was normalized by the amount of β-actin, a housekeeping gene that was used as endogenous control.

Statistical analysis

Non-parametric Kruskal-wallis was used to test the significant difference of PUMA upregulation between doxorubicin and EPMC.

Results and Discussion

In brief, we used MTT assay to test whether EPMC induced cytotoxicity in human lung adenocarcinoma cell lines A549 (p53 wild-type) and H1299 (p53 null). The cells were exposed to graded concentrations of EPMC (0-20 µg/mL). EPMC was found to decrease cells viability in a dose-dependent manner in the presence of p53 (Figure 1). However, in the absence of p53, EPMC did not induce cytotoxicity and cell death (Figure 2).

The findings of this study would seem to suggest that presence of the p53 gene is a key factor for sensitivity to anticancer agents (El Deiry *et al.*, 2003). The H1299 cell line has a recognized p53 gene deletion in both alleles. Thus, p53-null cells succumb to tumorigenesis. Unlike p53-null, p53 wild-type have the ability to suppress malignant growth of transformed cells as well as tumors. Therefore, compounds that activate wild-type p53 would have an application for the treatment of wt-p53 containing human cancer. Nevertheless, mutated p53 confers to the resistance of tumor cells to anticancer drugs by inhibiting p53-dependent pathway (Volgstein *et al.*, 2000).

The cytotoxicity of EPMC on human lung cancer cell line was compared against doxorubicin, a well-known chemotherapeutic agent as a positive control. EPMC and doxorubicin both induced the cytotoxic activity of p53 wild-type.

We next sought to determine whether EPMC was involved in the p53 pathway in A549 and H1299 cell lines through the expression of p53 mediated target genes (Beckerman *et al.*, 2010). The p53 mediated target genes assessed in the study were p21 and PUMA.

As shown in Figure 3, p21 expression levels were not induced in both cancer cell lines after incubation with EPMC. However, PUMA expression levels in both cancer cell lines increased after treatment with EPMC (Figure 4). Non-parametric Kruskal-Wallis statistical analysis was used to test for significant differences in PUMA upregulation upon treatment with doxorubicin and EPMC. No significant difference in PUMA upregulation between doxorubicin and EPMC was found. This indicates that EPMC is a potent treatment candidate for cancer. Furthermore, from the graph obtained it showed that the increment was more pronounced in A549 (p53 wild-type).

In a previous study, PUMA was reported to play an important role in benzyl isothiocyanate (BITC)-induced apoptosis. In the study, treatment with BITC clearly

increased the level of PUMA in cells with wild-type p53 (MCF-7) (Anthony *et al.*, 2012).




Figure 1. Ethyl-p-methoxycinnamate (EPMC) treatment schedules, EPMC dependent cytotoxicity and induced cell death in the presence of p53.




Figure 2. Ethyl-p-methoxycinnamate (EPMC) does not induce cytotoxicity and cell death in dose dependent manner in the absence of p53.




Figure 3. The graph shows that mRNA expression was not induced by EPMC incubation in both; A549 (p53 wild-type) and H1299 (p53 null) cancer cell line.




Figure 4. RT-PCR analysis revealed that mRNA expression levels were upregulated in both; A549 (p53 wild-type) and H1299 (p53 null) cancer cell line.

Nevertheless, the upregulation of PUMA mRNA expression does not indicate the involvement of the p53 pathway. This is because PUMA can also

be activated independently and thus plays a role in p53-independent apoptosis as in the case of the p53 homolog p73, which is

able to engage the PUMA promoter at the p53 response elements (Li *et al.*, 2006).

Thus, in this study EPMC is shown to stimulate cytotoxic and apoptotic effects on human lung cancer cell lines. However, the apoptotic effect of EPMC does not involve the p53 pathway.

Acknowledgement

This research was partially supported by the grant program from the International Islamic University Malaysia, Research Endowment Fund Grant No.IIUM REF-EDW B14-102-0987.

References

- Amuamuta, A., Plengsuriyakarn, T., & Na-Bangchang, K. (2017). Anticholangiocarcinoma activity and toxicity of the *Kaempferia galanga* Linn. Rhizome ethanolic extract. *BMC Complementary and Alternative Medicine*, 17(1), 213.
- Antony, M. L., Kim, S. H., & Singh, S. V. (2012). Critical role of p53 upregulated modulator of apoptosis in benzyl isothiocyanate-induced apoptotic cell death. *PLoS One*, 7(2).
- Bai, L., & Wang, S. (2014). Targeting apoptosis pathways for new cancer therapeutics. *Annual Review of Medicine*, 65, 139-155.
- Beckerman, R., & Prives, C. (2010). Transcriptional regulation by p53. *Cold Spring Harbor Perspectives in Biology*, 2(8), a000935.
- Chiang, M. F., Chou, P. Y., Wang, W. J., Sze, C. I., & Chang, N. S. (2013). Tumor suppressor WWOX and p53 alterations and drug resistance in glioblastomas. *Frontiers in Oncology*, 3, 43.
- El-Deiry, W. S. (2003). The role of p53 in chemosensitivity and radiosensitivity. *Oncogene*, 22(47), 7486-7495.
- Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017). The role of p53 in cancer drug resistance and targeted chemotherapy. *Oncotarget*, 8(5), 8921.
- Ichwan, S. J., Al-Ani, I. M., Bilal, H. G., Suriyah, W. H., Taher, M., & Ikeda, M. A. (2014). Apoptotic activities of thymoquinone, an active ingredient of black seed (*Nigella sativa*), in cervical cancer cell lines. *Chinese Journal of Physiology*, 57(5), 249-255.
- Ichwan, S. J., Husin, A., Suriyah, W. H., Lestari, W., Omar, M. N., & Kasmuri, A. R. (2019). Anti-neoplastic potential of ethyl-p-methoxycinnamate of *Kaempferia galanga* on oral cancer cell lines. *Materials Today: Proceedings*, 16, 2115-2121.
- Khoury, K., & Domling, A. (2012). P53 mdm2 inhibitors. *Current Pharmaceutical Design*, 18(30), 4668-4678.
- Klein, C., & Vassilev, L. T. (2004). Targeting the p53-MDM2 interaction to treat cancer. *British Journal of Cancer*, 91(8), 1415-1419.
- Li, J., Lee, B., & Lee, A. S. (2006). Endoplasmic reticulum stress-induced apoptosis multiple pathways and activation of p53-up-regulated modulator of apoptosis (puma) and noxa by p53. *Journal of Biological Chemistry*, 281(11), 7260-7270.
- Omar, M. N., Hasali, N. H. M., & Yarmo, M. A. (2016). Cytotoxicity Activity of Biotransformed ethyl p-methoxycinnamate by *Aspergillus niger*. *Oriental Journal of Chemistry*, 32(5), 2731-2734.
- Omar, M. N., Rahman, S. A., Ichwan, S. J. A., Hasali, N. H. M., Rasid, F. A., & Halim, F. A. (2017). Cytotoxicity effects of extracts and essential oil of *Kaempferia galanga* on cervical cancer C33A cell line. *Oriental Journal of Chemistry*, 33, 1659-1664.
- Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. *Nature*, 408(6810), 307-310.
- Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012). Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics. In *Protein-protein interactions* (pp. 57-79). Springer, Berlin, Heidelberg.
- Wang, Z., & Sun, Y. (2010). Targeting p53 for novel anticancer therapy. *Translational Oncology*, 3(1), 1-12.

Instruction to Authors

Submission

Complete manuscripts, written in English along with tables and illustrations should be submitted as softcopy to zainulrajion@iium.edu.my

Conditions

All manuscripts submitted for publication must be accompanied by a cover letter declaring originality of the work and certifies that the manuscript has not been published or submitted elsewhere, free from conflict of interest and conduct of research in accordance to ethical guidelines established for human subjects and animal welfare. In addition, a statement of agreement of all authors to transfer all the copyrights to the journal should also accompany the manuscript.

A copy of the certification form, which certifies that the manuscript has not been published or submitted before and all authors have contributed and are in agreement with the content of the manuscript, must be submitted to the journal's editorial office by uploading it as a PDF file.

Manuscripts submitted for publication are understood to be offered only to **IJOHS** and which have not been sent to other journals for consideration. There is no publication fee to submit or publish content in **IJOHS**.

Manuscript should be typed in **Arial, font size 11 with 1.5 spacing**.

The manuscript should be divided into the following sections with the sequence; Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Illustrations and Figure Legends must be incorporated near to the text they are cited

Title Page:

Title page should be arranged in the following order: (1) a concise and informative title not exceeding 80 characters; (2) authors' full names (without degrees and titles) and affiliation including city and country. Superscript numbers may be used to affiliate authors to different departments or institutions; and (3) a complete mailing address, telephone, fax and e-mail address of the corresponding author.

Abstract:

Abstract should be unstructured and should not exceed 250 words. It should be a self-standing summary of the work that may be republished by information retrieval services. A maximum of 5 keywords should be listed at the end of the abstract.

Introduction:

Introduction should briefly and clearly describe the background and objective(s) of the study. Avoid exhaustive review of the literature and include only relevant recent studies.

Materials and Methods:

This section should be described in sufficient details so that it is reproducible. It should include technical information such as the study design, and specific procedures. Sub-headings may be used to enhance the clarity or to categorize the methods. Established methods or procedures should be named and cited. New methods or modifications of old methods should be described with complete details. Authors are advised to use generic names and terms rather than commercial names. Statistical methods applied, software used must also be stated clearly and concisely.

Results:

This section should be presented in a logical sequence in text, tables and illustrations. Subheadings may be used

to enhance clarity or to call attention to the most significant findings. Data appearing in tables or figures may be summarized but not duplicated in the text. Tables and figures should be numbered in the order in which they are described and cited in the text. Example, For tables, examples are Table 1, Table 2 and for figures, examples are Figure 1, Figure 2.

Discussion:

This section should summarize, explain and interpret the results with a scientifically critical view of previously published works in the field. Avoid repetition of the data already presented in the result section.

Acknowledgements:

This section is to be given to those who have provided assistance to the project and sponsors who have given financial support and funds.

References:

This section should list all sources cited in the paper. The citations should be arranged in alphabetical order by the surname of the first author without numbering in the text. Cite article as e.g. (Ahmad, 2016) for a single author, (Chu & Kim, 2019) for two authors and (Karim *et al.*, 2013) for more than three authors.

Standard journal article

References to journals should provide the name(s) of the author(s), year, title of the paper and journal, volume and issue number, page numbers. Please provide full name of journal. If there are more than six authors, the first six authors should be listed and followed by *et al.* in the list of References.

Sudbery, P. E. (2011). Growth of *Candida albicans* Hyphae. *Nature Reviews Microbiology*, 9(10), 737.

Book

References to books/monographs should give the name(s) of the author(s), year, title of book, edition number, place of publication, publisher and page numbers.

Conn, E.E., Stumpf, P.K., Brueing, G., Doi, R.H. (1987). *Outlines of Biochemistry*, 3rd edn. New York: John Wiley & Sons, pp. 45–52.

Chapter in book

References to chapter in books/monographs should give the name(s) of the author(s), year, chapter title, editors, title of book, edition number, place of publication, publisher and page numbers.

Fejerskov O, Nyvad B, Kidd EAM (2003). Clinical and histological manifestations of dental caries. In: Fejerskov O, Kidd EAM (eds.), *Dental Caries – The Disease and Its Clinical Management*. London: Blackwell Munksgaard, pp. 71–97.

Internet resources

Authors are required to include as much electronic retrieval information as needed for others to locate the sources they have cited.

López-Jornet P (2006). Labial mucocele: a study of eighteen cases. *The Internet Journal of Dental Science*, 3(2). Retrieved 7 February 2007, from <http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijds/vol3n2/labial.xml>

Tables

Each table should have a suitable title with footnotes wherever necessary. Do not use vertical lines in the table.

Illustrations

All figures and illustrations could be original photographs, artwork or high-quality digital images (submitted as CMYK - 8 bits per channel in TIFF format). Images must be at least 600 by 450 pixels (proportional height) in size when in landscape orientation with a resolution of at least 300 pixels per inch. Graphs should be approximately 500 pixels wide so that all labeling can be read with data points clearly visible. Figures should be numbered

consecutively in the order in which they appear in the manuscript, using Arabic numerals. A list of figure legends must be included on a separate page following the illustrations. The legend should explain each figure in detail. All figures will be printed as black and white. Colour figures will only appear in the PDF file.

Page proofs

On acceptance of the manuscripts for publication, page proofs should be reviewed meticulously by the contributors. Changes made in proof should be limited to the correction of typographical errors. Proofs must be returned for publication with corrections and responses to queries on the date specified by the Editor.



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونِسُورِيَتِي اِسْلَامِيَّة اِنْتَرَا اِنجيسَا مَلِيسِيَا

Garden of Knowledge and Virtue